Lilly's Obesity Pill: 1,390 Scripts in Debut Week

Initial Prescription Data Released

Eli Lilly's recently launched oral obesity drug secured 1,390 prescriptions in the United States during its inaugural week ending April 10. This initial market data comes from an analyst report citing figures from healthcare data firm IQVIA.

Market Context and Competitor Comparison

The prescription numbers provide an early benchmark for the drug's entry into the highly competitive U.S. obesity treatment market. For comparison, key rival Novo Nordisk's oral Wegovy achieved 3,071 U.S. prescriptions within the first four days following its launch on January 5.

Potential Market Impact

These early figures are a critical indicator for investors monitoring the performance of new entrants in the lucrative weight-loss drug sector. The initial uptake reflects early physician and patient interest, setting a baseline for tracking the drug's market trajectory against established competitors.

Summary

While Eli Lilly's debut shows a solid start, the initial prescription volume is notably lower than that of its primary competitor's launch. Market analysts will closely watch subsequent weekly data to assess growth momentum and determine its potential market share in the expanding obesity drug landscape.

FAQ

Q: How many prescriptions did Eli Lilly's new obesity pill receive in its first week?
A: The drug was prescribed 1,390 times in the U.S. for the week ending April 10.

Q: How does this launch compare to Novo Nordisk's Wegovy?
A: Novo Nordisk's oral Wegovy recorded 3,071 prescriptions in its first four days of availability.

Source: Investing.com